Opendata, web and dolomites


Personalized, bio-engineered skin grafts for the permanent treatment of skin defects.

Total Cost €


EC-Contrib. €






 denovoSkin project word cloud

Explore the words cloud of the denovoSkin project. It provides you a very rough idea of what is the project "denovoSkin" about.

meet    world    designation    movement    ema    significantly    function    performance    hence    epidermal    deployment    economic    trade    structure    sized    chain    fast    classified    fits    avoids    invested    considerable    drug    automation    reduce    intervention    surgical    financial    patented    permanent    painful    solving    starting    bio    transplantation    rehabilitation    scar    autografting    therapy    life    leaves    sound    commercialisation    treatment    sme    plan    off    suffer    minimally    patient    excision    interventions    50m    every    quality    14m    outstanding    denovoskin    human    graft    burns    fda    follow    shortage    care    savings    orphan    16    debilitating    standard    market    57m    global    projected    wounds    engineered    health    skin    last    granted    clinical    investment    burden    personalized    disfiguring    medical    quantities    demand    swissmedic    instrument    homecare    corrective    patients    dermo    psychosocial    issue    intense    manufacture    considerably    scars    atmp    stamp    restore    site    surgeries    biopsy    donor    impair    solid    defects   

Project "denovoSkin" data sheet

The following table provides information about the project.


Organization address
city: ZURICH
postcode: 8006
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2018-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CUTISS AG CH (ZURICH) coordinator 50˙000.00


 Project objective

Every year in the world, more than 50M patients suffer from skin defects (e.g. burns, excision, etc.) and need surgical intervention to restore skin function. Standard of care, skin autografting, very often leaves these patients with scars. Scars are permanent and disfiguring, and can also be painful and highly debilitating. Indeed, they may also impair movement and growth, and require several follow-up surgeries, intense homecare and psychosocial rehabilitation. Hence, scars significantly affect patient’s quality of life, along with the economic burden for the health-care system. Furthermore, in the case of large wounds, donor site shortage represents a real clinical issue. denovoSkin™ is a patented, personalized, bio-engineered human skin graft classified as Advanced Therapy Medical Product (ATMP). It is engineered in large quantities starting-off from a stamp-sized skin biopsy of the patient, thus solving the donor site shortage issue. Moreover, because of its dermo-epidermal structure, denovoSkin is expected to minimally scar after transplantation. Its outstanding performance could considerably reduce or even avoids further corrective interventions, allowing for considerable savings in terms of costs. denovoSkin™ is granted with Orphan Drug Designation for the treatment of burns by Swissmedic, EMA and FDA. So far, more than €14M have been invested over the last 16 years of research into the development and the clinical testing of denovoSkin™. To have denovoSkin™ fully projected at a European and global level we need a further investment of €3.57M to set up a solid EU value chain able to meet the large demand expected during the commercialisation via developing the automation of manufacture. The proposed work in Phase 1 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of denovoSkin™ and its market uptake.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DENOVOSKIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DENOVOSKIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)


Super Productive Line Printing Inkjet

Read More  

HelpingHAND (2018)

A 3D printed, affordable myoelectrical prosthetic hand of personalizeable size for optimal comfort and functionality

Read More  

STAR (2018)

Safe, Transparent, Active and Reliable mineral sunscreen technology

Read More